COMMUNIQUÉS West-GlobeNewswire

Protalix BioTherapeutics Announces Final Dosing of Last Patient in Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis
15/02/2018
CARMIEL, Israel, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE: PLX ), announced today the final dosing of the last patient in the Company’s phase II clinical trial [...]
Asterias Expands Global IP Portfolio with New Patents, Including Key Additional Patent Protection for its Cancer Immunotherapy Program
15/02/2018
FREMONT, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing regenerative medicine therapeutics to treat neurological conditions [...]
Antares Pharma Announces FDA Approval of Partner’s Product Utilizing Our QuickShot Auto Injector
15/02/2018
EWING, N.J., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS ) today announced the successful regulatory outcome of the Makena ® subcutaneous auto injector collaboration with AMAG Pharmaceuticals ( [...]
Merit Medical Closes Deal With BD for Purchase of Divestment Assets
15/02/2018
SOUTH JORDAN, Utah, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI ), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic [...]
Active Biotech announces rights issue of approximately SEK 48 million
15/02/2018
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD [...]
Zealand Pharma's dasiglucagon Phase 2a results at the 11th International Conference on ATTD
15/02/2018
Press release - No. 3/2018 Zealand Pharma's dasiglucagon Phase 2a results will be presented at the 11th International Conference on Advanced Technologies & Treatments for Diabetes Dasiglucagon was dosed using the [...]
NOTICE OF EXTRAORDINARY SHAREHOLDERS' MEETING
15/02/2018
The shareholders of Active Biotech AB (publ) are invited to the Extraordinary Shareholders' Meeting to be held on Monday 19 March 2018, at 5 pm at the company's offices, Scheelevägen 22 in Lund, Sweden. ENTITLEMENT TO [...]
Active Biotech carries out rights issue
15/02/2018
Read the press release here Attachments: http://www.globenewswire.com/NewsRoom/AttachmentNg/d7099433-338a-49f0-bf4b-5255146611fb
Active Biotech AB Year-end report January - December 2017
15/02/2018
Fourth quarter in brief The primary clinical endpoint was not met in the Phase II study (ARPEGGIO) with laquinimod in PPMS Patent regarding tasquinimod for the treatment of acute leukemia granted in Europe The process [...]
Dow BioMedica to distribute Biohit GastroPanel® in Korea
15/02/2018
Biohit Oyj Press release, 15 th February, 2018 at 9.30 a.m. local time (EET) Biohit Oyj and Dow BioMedica have signed an agreement for the distribution of Biohit GastroPanel in Korea. The contract has been signed for [...]
Ossur Hf : Annual General Meeting 8 March 2018
15/02/2018
Announcement no. 10/2018 Reykjavik, 15 February 2018 Össur hf. - Annual General Meeting 8 March 2018 Össur hf.'s Annual General Meeting will be held on Thursday, 8 March 2018, at 9:00 am (GMT) at the Company's offices [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
15/02/2018
REGULATED INFORMATION GHENT, Belgium, 15 February 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
Navamedic ASA: Q4 2017 results
15/02/2018
Oslo, February 15, 2018 - Navamedic ASA (OSE: NAVA), reported revenues of NOK 45.2 million in the fourth quarter of 2017, down from NOK 81.6 million in the same period in 2016, following the planned discontinuation of [...]
VALNEVA Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth
15/02/2018
Valneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth Strong sales performance in 2017 (unaudited) Total revenues of €109.8 million in 2017 (2016 - €97.9 million) representing year-on-year [...]
Valneva publie un très bon chiffre d'affaires 2017 soutenu par une croissance à deux chiffres des ventes de produits
15/02/2018
Valneva publie un très bon chiffre d'affaires 2017 soutenu par une croissance à deux chiffres des ventes de produits Forte croissance des ventes en 2017 (chiffres non audités) Chiffre d'affaires total de €109,8 millions [...]
Addex Launches CHF40 million Capital Increase with Commitment from Specialist US Healthcare Investors
15/02/2018
Proceeds will extend cash runway through 2022 and fund dipraglurant through the first pivotal registration study in PD-LID Geneva, Switzerland, 15 February 2018 - Addex Therapeutics (SIX: ADXN), the leading developer of [...]
Targovax ASA: Fourth quarter and full year 2017 results
15/02/2018
Oslo, Norway, 15 February 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its third quarter 2017 results. A meeting for [...]
Addex Launches CHF40 million Capital Increase with Commitment from Specialist US Healthcare Investors
15/02/2018
Proceeds will extend cash runway through 2022 and fund dipraglurant through the first pivotal registration study in PD-LID Geneva, Switzerland, 15 February 2018 - Addex Therapeutics (SIX: ADXN), the leading developer of [...]
MDxHealth Notice of Financial Year 2017 Results
15/02/2018
COMPANY ANNOUNCEMENT REGULATED INFORMATION INSIDE INFORMATION MDxHealth Notice of Financial Year 2017 Results Conference call for analysts and investors to be held on 22 February 2018 at 15:00 CET IRVINE, CA, and [...]

Pages